# RDR-006 — CLOSURE

**Project:** 12-Gene Gastric Cancer Signature — Part 2: Modernized Biomarker Discovery Framework
**Closes:** RDR-006_Interpretability_and_Clinical_Translation_Methodology.md
**Status at closure:** LOCKED (APPROVED — Project Coordinator confirmed)

---

## Executive Summary

RDR-006 specializes the framework's architecture and methodology governance (RDR-001, RDR-002) for the Interpretability and Clinical Translation Layer, building on the already-locked Phase A philosophy and on RDR-003 through RDR-005. It defines this layer's internal three-stage architecture (Biological Interpretation → Model Explanation → Clinical Translation), the standardized Enrichment Evidence package, benchmarking philosophy against Part 1's historical clinical translation pathway, the layer's boundary with Framework Integration, and governance treatment of the Validated Candidate it enriches. Unlike RDR-003 through RDR-005, this document introduces no new candidate type: the Validated Candidate, together with its Enrichment Evidence, remains the same artifact throughout. The document passed one revision cycle (three targeted refinements, no redesign) and is now locked as-is. With this lock, the methodology specialization series (RDR-003–RDR-006) is complete.

---

## Locked Decisions

- The Interpretability and Clinical Translation Layer's internal architecture is fixed as a three-stage sequence: Biological Interpretation → Model Explanation → Clinical Translation, operating on the Validated Candidate and producing the Validated Candidate together with Enrichment Evidence as output.
- This three-stage sequence is itself subject to component-wise, evidence-constrained modernization (RDR-002); each stage may be independently modernized, retained, deferred, or rejected once a specific methodology proposal is brought forward.
- **No new candidate type is created.** The Validated Candidate, together with its Enrichment Evidence, remains scientifically and architecturally the same Validated Candidate that entered this layer; its Model Candidate and Discovery Candidate lineage remains unchanged and fully traceable. Terminology implying a new artifact (e.g., "Enriched Validated Candidate" as a distinct class) was explicitly revised out of the document during this revision cycle.
- **Enrichment Evidence** is locked as the standardized evidence package for this layer — biological interpretation evidence, model explanation evidence, clinical translation evidence — symmetric with Discovery Evidence (RDR-003), Model Evidence (RDR-004), and Validation Evidence (RDR-005). No new evidence component beyond these three was introduced.
- **Enrichment Evidence extends, rather than replaces, Validation Evidence.** It builds directly upon the already-completed Validation Evidence (RDR-005, Section 7) rather than superseding, duplicating, or re-deriving it, preserving the standardized evidence-package pattern consistently applied across the framework.
- **Benchmarking Philosophy:** the historical Part 1 clinical translation pathway (Nomogram, Calibration, Decision Curve Analysis, bootstrap) must remain directly executable within this layer's three-stage architecture, enabling genuine stage-level benchmarking; historical methodology remains one governed pathway, not a baseline to be replaced.
- **Layer Boundary:** the downstream progression Validated Candidate → Interpretability & Clinical Translation (enrichment) → Framework Integration is confirmed. Framework-wide reporting, scientific communication, clinical reporting, the Framework-Wide Recommendation, end-to-end framework presentation, and final integrated framework outputs are explicitly out of scope for RDR-006 and belong to Framework Integration.
- **Governance:** no layer-specific candidate governance section is introduced, and this is explicitly a deliberate governance choice rather than an omission — because no new candidate type exists, the existing Validated Candidate Governance (RDR-005, Section 10) already applies in full and remains sufficient.

---

## Newly Approved Concepts

No new architectural concepts were introduced beyond what Phase A already locked. The single revision cycle applied three targeted refinements that clarified terminology and strengthened existing locked philosophy, without expanding the architecture:

- Replacement of "Enriched Validated Candidate" wording throughout the document with "Validated Candidate, together with Enrichment Evidence," making explicit that no new candidate artifact is created.
- Explicit statement, added to Section 7, that Enrichment Evidence extends rather than replaces Validation Evidence.
- Explicit rationale, added to Section 10 (Governance), for why no layer-specific candidate governance section is needed — a deliberate consequence of the locked Candidate Philosophy, not an oversight.

---

## Remaining Open Questions

Explicitly deferred to a future, separately governed methodology proposal (per RDR-006 Section 11), and NOT resolved by this document:

- Which specific method instantiates Biological Interpretation, Model Explanation, or Clinical Translation.
- Any hyperparameter, software package, or implementation detail.
- The precise form or content of biological interpretation evidence, model explanation evidence, or clinical translation evidence beyond the requirement that each be documented.
- Any aspect of Framework Integration, including the Framework-Wide Recommendation, framework-wide reporting, and end-to-end presentation — explicitly reserved for that later, separately governed stage.

No architectural ideas were flagged as out-of-scope during this revision cycle; the three requested refinements were incorporated directly into the locked document.

---

## Downstream Documents Affected

- **Framework Integration** (next governance activity, conducted under separate governance) — must treat Validated Candidates, each together with their Enrichment Evidence, as the fixed starting input, and must independently define the Framework-Wide Recommendation, framework-wide reporting, and end-to-end presentation responsibilities that RDR-006 explicitly excluded.
- Any future methodology proposal for this layer's three internal stages must be evaluated through the Methodology Decision Layer (RDR-002) and is downstream of, not a revision to, this document.

---

## Governance Status

**Status:** LOCKED (APPROVED) — no further revision cycles permitted; RDR-006 is immutable.
**Implementation:** NOT PERMITTED

---

## Next Step

The methodology specialization series (RDR-003 Discovery → RDR-004 Modeling → RDR-005 Validation → RDR-006 Interpretability & Clinical Translation) is now complete. The project transitions from this RDR series to **Framework Integration**, conducted under separate governance:

1. Framework Integration Phase A (philosophy/scope discussion, conducted separately)
2. Lock the Framework Integration philosophy
3. Proceed with Framework Integration only after that philosophy is locked

---

## Handoff Notes

For any future thread continuing this project: **RDR-000 through RDR-006 are now fully locked**, together with their closures (RDR-002_CLOSURE through RDR-006_CLOSURE), all under PROJECT_GOVERNANCE_PROMPT_v4.5.1.md. No algorithm, statistical test, software package, or implementation detail has been named anywhere in the chain. **The methodology specialization series is complete**: Discovery (RDR-003), Modeling (RDR-004), Validation (RDR-005), and Interpretability & Clinical Translation (RDR-006) each fix an internal architecture, a standardized evidence package, a benchmarking philosophy against the corresponding historical Part 1 component, and a boundary to the next layer — with the candidate evolution Discovery Candidate → Model Candidate → Validated Candidate (enriched with Enrichment Evidence at RDR-006) now fully and consistently specified end to end.

**The next governance activity is Framework Integration, conducted under separate governance.** No previously locked RDR (RDR-000 through RDR-006) may be modified, redesigned, or reopened during Framework Integration or at any later stage; any future architectural evolution must occur through a new, separately governed document, never through retroactive modification of this chain. Framework Integration is responsible for the Framework-Wide Recommendation, the resulting Recommended Signature, framework-wide reporting, scientific communication, clinical reporting, and end-to-end framework presentation — none of which have been specified by any document in the RDR-000–RDR-006 chain, and all of which remain open for that separately governed stage.
